Gooderham, M., Spelman, L., Imafuku, S., Romanelli, M., Merola, J.F., Armstrong, A.W., Colston, E., Banerjee, S., Scharnitz, T. and Blauvelt, A. 2023. Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Efficacy by Baseline Demographic and Disease Characteristics in the Phase 3 POETYK PSO-1 and PSO-2 Trials. SKIN The Journal of Cutaneous Medicine. 7, 4 (Jul. 2023), s219. DOI:https://doi.org/10.25251/skin.7.supp.219.